GB201512215D0 - Agents,uses and methods - Google Patents

Agents,uses and methods

Info

Publication number
GB201512215D0
GB201512215D0 GBGB1512215.3A GB201512215A GB201512215D0 GB 201512215 D0 GB201512215 D0 GB 201512215D0 GB 201512215 A GB201512215 A GB 201512215A GB 201512215 D0 GB201512215 D0 GB 201512215D0
Authority
GB
United Kingdom
Prior art keywords
agents
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1512215.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Priority to GBGB1512215.3A priority Critical patent/GB201512215D0/en
Publication of GB201512215D0 publication Critical patent/GB201512215D0/en
Priority to JOP/2016/0141A priority patent/JO3710B1/ar
Priority to PL16739087.1T priority patent/PL3322726T3/pl
Priority to JP2018501182A priority patent/JP6979397B2/ja
Priority to UAA201800574A priority patent/UA125136C2/uk
Priority to PE2018000064A priority patent/PE20181014A1/es
Priority to TNP/2017/000534A priority patent/TN2017000534A1/en
Priority to RS20250507A priority patent/RS66856B1/sr
Priority to HK18113432.9A priority patent/HK1254356B/en
Priority to EP16739087.1A priority patent/EP3322726B1/en
Priority to HRP20250602TT priority patent/HRP20250602T1/hr
Priority to CR20180002A priority patent/CR20180002A/es
Priority to AU2016292980A priority patent/AU2016292980B2/en
Priority to US15/207,880 priority patent/US10428147B2/en
Priority to CN201680040476.5A priority patent/CN107849135A/zh
Priority to ES16739087T priority patent/ES3024469T3/es
Priority to CN202210124752.3A priority patent/CN114478775A/zh
Priority to KR1020187001192A priority patent/KR102778576B1/ko
Priority to CA2989739A priority patent/CA2989739A1/en
Priority to HUE16739087A priority patent/HUE071424T2/hu
Priority to EA201890038A priority patent/EA201890038A1/ru
Priority to TW105121903A priority patent/TWI760305B/zh
Priority to RU2018100824A priority patent/RU2735639C2/ru
Priority to MX2018000506A priority patent/MX2018000506A/es
Priority to PCT/EP2016/066516 priority patent/WO2017009327A1/en
Priority to MA42440A priority patent/MA42440B1/fr
Priority to BR112018000771-4A priority patent/BR112018000771A2/pt
Priority to ARP160102109A priority patent/AR105335A1/es
Priority to US15/743,549 priority patent/US10479835B2/en
Priority to CN202210124751.9A priority patent/CN114478774A/zh
Priority to CONC2017/0012988A priority patent/CO2017012988A2/es
Priority to ZA2017/08613A priority patent/ZA201708613B/en
Priority to IL256503A priority patent/IL256503B/en
Priority to NI201800007A priority patent/NI201800007A/es
Priority to PH12018500100A priority patent/PH12018500100A1/en
Priority to DO2018000014A priority patent/DOP2018000014A/es
Priority to SV2018005613A priority patent/SV2018005613A/es
Priority to CL2018000092A priority patent/CL2018000092A1/es
Priority to ECIEPI20182725A priority patent/ECSP18002725A/es
Priority to US16/521,279 priority patent/US10889650B2/en
Priority to CL2020002468A priority patent/CL2020002468A1/es
Priority to US17/097,457 priority patent/US11548950B2/en
Priority to JP2021151783A priority patent/JP2022003058A/ja
Priority to US18/057,104 priority patent/US12331123B2/en
Priority to US19/210,142 priority patent/US20250277040A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1512215.3A 2015-07-13 2015-07-13 Agents,uses and methods Ceased GB201512215D0 (en)

Priority Applications (45)

Application Number Priority Date Filing Date Title
GBGB1512215.3A GB201512215D0 (en) 2015-07-13 2015-07-13 Agents,uses and methods
JOP/2016/0141A JO3710B1 (ar) 2015-07-13 2016-07-11 أجسام مضادة ترتبط بسورتيلين وتثبط ارتباط البروجرانولين
CN202210124751.9A CN114478774A (zh) 2015-07-13 2016-07-12 与分拣蛋白结合并抑制颗粒蛋白前体的结合的抗体
MX2018000506A MX2018000506A (es) 2015-07-13 2016-07-12 Agentes, usos y metodos para el tratamiento.
JP2018501182A JP6979397B2 (ja) 2015-07-13 2016-07-12 ソルチリンに結合し、プログラニュリンの結合を阻害する抗体
UAA201800574A UA125136C2 (uk) 2015-07-13 2016-07-12 Антитіла, які зв'язуються з сортиліном і пригнічують зв'язування програнуліну
PE2018000064A PE20181014A1 (es) 2015-07-13 2016-07-12 Agentes, usos y metodos para el tratamiento
TNP/2017/000534A TN2017000534A1 (en) 2015-07-13 2016-07-12 Antibodies that bind to sortilin and inhibit the binding of progranulin
RS20250507A RS66856B1 (sr) 2015-07-13 2016-07-12 Antitela koja se vezuju za sortilin i inhibiraju vezivanje progranulina
HK18113432.9A HK1254356B (en) 2015-07-13 2016-07-12 Antibodies that bind to sortilin and inhibit the binding of progranulin
EP16739087.1A EP3322726B1 (en) 2015-07-13 2016-07-12 Antibodies that bind to sortilin and inhibit the binding of progranulin
HRP20250602TT HRP20250602T1 (hr) 2015-07-13 2016-07-12 Antitijela koja se vežu na sortilin i inhibiraju vezanje progranulina
CR20180002A CR20180002A (es) 2015-07-13 2016-07-12 Agentes, usos y métodos para el tratamiento
AU2016292980A AU2016292980B2 (en) 2015-07-13 2016-07-12 Antibodies that bind to Sortilin and inhibit the binding of progranulin
US15/207,880 US10428147B2 (en) 2015-07-13 2016-07-12 Anti-sortilin antibodies, uses and methods for treatment
CN201680040476.5A CN107849135A (zh) 2015-07-13 2016-07-12 与分拣蛋白结合并抑制颗粒蛋白前体的结合的抗体
ES16739087T ES3024469T3 (en) 2015-07-13 2016-07-12 Antibodies that bind to sortilin and inhibit the binding of progranulin
CN202210124752.3A CN114478775A (zh) 2015-07-13 2016-07-12 与分拣蛋白结合并抑制颗粒蛋白前体的结合的抗体
KR1020187001192A KR102778576B1 (ko) 2015-07-13 2016-07-12 소르틸린에 결합하고 프로그라눌린의 결합을 억제하는 항체
CA2989739A CA2989739A1 (en) 2015-07-13 2016-07-12 Antibodies that bind to sortilin and inhibit the binding of progranulin
HUE16739087A HUE071424T2 (hu) 2015-07-13 2016-07-12 Szortilinhez kötõdõ és a progranulin kötõdését gátló antitestek
EA201890038A EA201890038A1 (ru) 2015-07-13 2016-07-12 Антитела, которые связываются с сортилином и подавляют связывание програнулина
TW105121903A TWI760305B (zh) 2015-07-13 2016-07-12 抗分揀蛋白抗體、包含其之組成物與套組及其用途
PL16739087.1T PL3322726T3 (pl) 2015-07-13 2016-07-12 Przeciwciała wiążące się z sortyliną i hamujące wiązanie progranuliny
PCT/EP2016/066516 WO2017009327A1 (en) 2015-07-13 2016-07-12 Antibodies that bind to sortilin and inhibit the binding of progranulin
RU2018100824A RU2735639C2 (ru) 2015-07-13 2016-07-12 Антитела, которые связываются с сортилином и подавляют связывание програнулина
MA42440A MA42440B1 (fr) 2015-07-13 2016-07-12 Anticorps contre la sortilin qui inhibent la liason à la progranulin
BR112018000771-4A BR112018000771A2 (pt) 2015-07-13 2016-07-12 anticorpos que se ligam à sortilina e inibem a ligação de progranulina, composições farmacêuticas, preparações dos mesmos, uso de anticorpos, kit e método de prevenção ou tratamento de uma doença associada a níveis diminuídos de pgrn
ARP160102109A AR105335A1 (es) 2015-07-13 2016-07-12 Anticuerpos monoclonales anti-sortilina
US15/743,549 US10479835B2 (en) 2015-07-13 2016-07-12 Agent, uses and methods for treatment
ZA2017/08613A ZA201708613B (en) 2015-07-13 2017-12-18 Antibodies that bind to sortilin and inhibit the binding of progranulin
CONC2017/0012988A CO2017012988A2 (es) 2015-07-13 2017-12-18 Agentes, usos y métodos para el tratamiento
IL256503A IL256503B (en) 2015-07-13 2017-12-22 Antibodies that bind sortilin and inhibit binding to progranulin
NI201800007A NI201800007A (es) 2015-07-13 2018-01-11 Agentes, usos y métodos para el tratamiento
PH12018500100A PH12018500100A1 (en) 2015-07-13 2018-01-11 Antibodies that bind to sortilin and inhibit the binding of progranulin
DO2018000014A DOP2018000014A (es) 2015-07-13 2018-01-11 Anticuerpos que se unen a la sortilina e inhiben la vinculación de progranulina
SV2018005613A SV2018005613A (es) 2015-07-13 2018-01-11 Agentes, usos y metodos para el tratamiento
CL2018000092A CL2018000092A1 (es) 2015-07-13 2018-01-11 Anticuerpos que se unen a la sortilina e inhiben la union de progranulina.
ECIEPI20182725A ECSP18002725A (es) 2015-07-13 2018-01-12 Agentes, usos y métodos para el tratamiento
US16/521,279 US10889650B2 (en) 2015-07-13 2019-07-24 Agent, uses and methods for treatment
CL2020002468A CL2020002468A1 (es) 2015-07-13 2020-09-24 Anticuerpos que se unen a la sortilina e inhiben la union de progranulina.(divisional de solicitud 92-2018)
US17/097,457 US11548950B2 (en) 2015-07-13 2020-11-13 Agent, uses and methods for treatment
JP2021151783A JP2022003058A (ja) 2015-07-13 2021-09-17 ソルチリンに結合し、プログラニュリンの結合を阻害する抗体
US18/057,104 US12331123B2 (en) 2015-07-13 2022-11-18 Agent, uses and methods for treatment
US19/210,142 US20250277040A1 (en) 2015-07-13 2025-05-16 Agent, uses and methods for treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1512215.3A GB201512215D0 (en) 2015-07-13 2015-07-13 Agents,uses and methods

Publications (1)

Publication Number Publication Date
GB201512215D0 true GB201512215D0 (en) 2015-08-19

Family

ID=54013862

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1512215.3A Ceased GB201512215D0 (en) 2015-07-13 2015-07-13 Agents,uses and methods

Country Status (35)

Country Link
US (6) US10479835B2 (https=)
EP (1) EP3322726B1 (https=)
JP (2) JP6979397B2 (https=)
KR (1) KR102778576B1 (https=)
CN (3) CN107849135A (https=)
AR (1) AR105335A1 (https=)
AU (1) AU2016292980B2 (https=)
BR (1) BR112018000771A2 (https=)
CA (1) CA2989739A1 (https=)
CL (2) CL2018000092A1 (https=)
CO (1) CO2017012988A2 (https=)
CR (1) CR20180002A (https=)
DO (1) DOP2018000014A (https=)
EA (1) EA201890038A1 (https=)
EC (1) ECSP18002725A (https=)
ES (1) ES3024469T3 (https=)
GB (1) GB201512215D0 (https=)
HR (1) HRP20250602T1 (https=)
HU (1) HUE071424T2 (https=)
IL (1) IL256503B (https=)
JO (1) JO3710B1 (https=)
MA (1) MA42440B1 (https=)
MX (1) MX2018000506A (https=)
NI (1) NI201800007A (https=)
PE (1) PE20181014A1 (https=)
PH (1) PH12018500100A1 (https=)
PL (1) PL3322726T3 (https=)
RS (1) RS66856B1 (https=)
RU (1) RU2735639C2 (https=)
SV (1) SV2018005613A (https=)
TN (1) TN2017000534A1 (https=)
TW (1) TWI760305B (https=)
UA (1) UA125136C2 (https=)
WO (1) WO2017009327A1 (https=)
ZA (1) ZA201708613B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3280441T1 (sl) 2015-04-07 2022-01-31 Alector Llc Protitelesa anti-sortilin in metoda njihove uporabe
WO2016164608A1 (en) 2015-04-07 2016-10-13 Alector Llc Methods of screening for sortilin binding antagonists
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10894833B2 (en) * 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
LT3618928T (lt) 2018-07-13 2023-04-11 Alector Llc Anti-sortilino antikūnai ir jų panaudojimo būdai
EP3666281A1 (en) * 2018-12-14 2020-06-17 Insusense ApS Compositions comprising sortilin-1
MX2021012335A (es) * 2019-04-10 2021-11-12 Regeneron Pharma Anticuerpos humanos que se unen a ret y metodos de uso de los mismos.
PH12022551598A1 (en) * 2019-12-23 2023-11-20 Denali Therapeutics Inc Progranulin variants
BR112022026508A2 (pt) * 2020-06-24 2023-03-07 Prothena Biosciences Ltd Anticorpos que reconhecem sortilina
KR20250028349A (ko) 2022-06-23 2025-02-28 드라우프니르 바이오 에이피에스 리소좀 내 세포외 표적의 분해를 선택적으로 유도하는 이작용성 분자
CN118496354A (zh) * 2023-02-15 2024-08-16 三优生物医药(上海)有限公司 包含共同轻链的抗体库、其制备方法及其用途
WO2025031098A1 (zh) * 2023-08-09 2025-02-13 瑞诺元(苏州)生物科技有限公司 一种分拣蛋白1特异性的纳米抗体、含有其的重组aav及应用
WO2025132764A1 (en) * 2023-12-21 2025-06-26 Amylonix Ab A sortilin-binding polypeptide

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0486622T3 (da) 1989-08-09 1999-07-19 Rhomed Inc Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5101990A (en) 1990-03-23 1992-04-07 Continental Pet Technologies, Inc. Stretch blow molded oblong or oval container
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
CA2113113A1 (en) 1991-07-08 1993-01-21 Simon W. Kantor Thermotropic liquid crystal segmented block copolymer
WO1994019935A1 (en) 1993-03-09 1994-09-15 Genzyme Corporation Isolation of components of interest from milk
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
WO2000046147A2 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
MXPA02000962A (es) 1999-07-29 2002-07-02 Medarex Inc Anticuerpos monoclonales humanos para her2/neu.
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
EP1891966B1 (en) 2002-12-20 2012-02-15 H. Lundbeck A/S Modulation of activity of neurotrophins; screening method
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
WO2008076262A2 (en) 2006-12-15 2008-06-26 Merck & Co., Inc. Receptor for amyloid beta and uses thereof
RS60019B1 (sr) 2006-12-21 2020-04-30 H Lundbeck As Modulacija aktivnosti proneurotrofina
JP5588866B2 (ja) 2007-08-10 2014-09-10 メダレックス エル．エル．シー． Ｈｃｏ３２およびｈｃｏ２７、ならびに関連実施例
KR101614558B1 (ko) 2008-04-27 2016-04-22 하. 룬드벡 아크티에셀스카브 인간 소르틸린의 결정 구조 및 소르틸린에 대한 리간드를 확인하기 위한 이의 용도
WO2009154995A2 (en) 2008-05-27 2009-12-23 Kyowa Hakko Kirin Co., Ltd. Interleukin 10 receptor (il-10r) antibodies and methods of use
US20120039865A1 (en) 2008-08-19 2012-02-16 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
EP3165537A1 (en) * 2008-12-19 2017-05-10 H. Lundbeck A/S Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders
RU2536232C2 (ru) * 2011-07-01 2014-12-20 Олег Ильич Эпштейн Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
JP6239635B2 (ja) 2012-11-02 2017-11-29 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 血管石灰化の誘導因子であるソルチリン１
SI3280441T1 (sl) 2015-04-07 2022-01-31 Alector Llc Protitelesa anti-sortilin in metoda njihove uporabe
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
LT3618928T (lt) 2018-07-13 2023-04-11 Alector Llc Anti-sortilino antikūnai ir jų panaudojimo būdai

Also Published As

Publication number Publication date
CL2018000092A1 (es) 2018-07-06
AU2016292980A1 (en) 2018-01-18
RU2018100824A3 (https=) 2020-01-17
CO2017012988A2 (es) 2018-05-21
EA201890038A1 (ru) 2018-06-29
MX2018000506A (es) 2018-05-11
TN2017000534A1 (en) 2019-04-12
JP2022003058A (ja) 2022-01-11
JP2018529635A (ja) 2018-10-11
US11548950B2 (en) 2023-01-10
MA42440B1 (fr) 2025-05-30
MA42440A (fr) 2018-05-23
US20200190188A1 (en) 2020-06-18
DOP2018000014A (es) 2018-04-15
HUE071424T2 (hu) 2025-08-28
PE20181014A1 (es) 2018-06-26
CN114478774A (zh) 2022-05-13
HRP20250602T1 (hr) 2025-07-18
ZA201708613B (en) 2021-03-31
HK1254356A1 (en) 2019-07-19
TWI760305B (zh) 2022-04-11
JP6979397B2 (ja) 2021-12-15
US20250277040A1 (en) 2025-09-04
CN107849135A (zh) 2018-03-27
CL2020002468A1 (es) 2021-01-29
US20210269524A1 (en) 2021-09-02
CN114478775A (zh) 2022-05-13
EP3322726A1 (en) 2018-05-23
UA125136C2 (uk) 2022-01-19
IL256503B (en) 2022-02-01
PL3322726T3 (pl) 2025-06-23
US10479835B2 (en) 2019-11-19
KR102778576B1 (ko) 2025-03-07
TW201702273A (zh) 2017-01-16
EP3322726C0 (en) 2025-03-12
US10428147B2 (en) 2019-10-01
KR20180030045A (ko) 2018-03-21
US20230159643A1 (en) 2023-05-25
US12331123B2 (en) 2025-06-17
RU2018100824A (ru) 2019-08-13
NI201800007A (es) 2018-10-18
PH12018500100A1 (en) 2018-07-30
AU2016292980B2 (en) 2022-10-06
BR112018000771A2 (pt) 2018-09-25
ES3024469T3 (en) 2025-06-04
AR105335A1 (es) 2017-09-27
US20180305455A1 (en) 2018-10-25
RU2735639C2 (ru) 2020-11-05
RS66856B1 (sr) 2025-06-30
IL256503A (en) 2018-02-28
US20170267761A1 (en) 2017-09-21
ECSP18002725A (es) 2018-03-31
JO3710B1 (ar) 2021-01-31
WO2017009327A1 (en) 2017-01-19
EP3322726B1 (en) 2025-03-12
CR20180002A (es) 2018-04-09
US10889650B2 (en) 2021-01-12
CA2989739A1 (en) 2017-01-19
SV2018005613A (es) 2018-02-23

Similar Documents

Publication Publication Date Title
GB201512203D0 (en) Agents,uses and methods
IL255577B (en) Binding materials - tigit and their uses
IL253433A0 (en) Binders - tnfrsf and their uses
IL249370A0 (en) Fap-enabled medical substances and related uses
SG11201608943VA (en) Substituted 4-phenylpiperidines, their preparaiton and use
GB201512215D0 (en) Agents,uses and methods
IL252430A0 (en) Antibodies, uses and methods
GB201603311D0 (en) New uses and methods
GB201408673D0 (en) Medicaments,uses and methods
ZA201801052B (en) Combinations and uses thereof
GB201715769D0 (en) Methods, Compositions and uses relating thereto
GB201612858D0 (en) New uses and methods
GB201715768D0 (en) Methods, compositions and uses relating thereto
GB201706349D0 (en) Methods, compositions and uses relating thereto
GB201616670D0 (en) Methods, compositions and uses relating thereto
GB2548839B (en) New uses and methods
IL254241A0 (en) Etv2 and its uses
PT3288575T (pt) Complexo de proteína-melanina bioassimilável, sua preparação e utilizações
GB201616674D0 (en) Methods, compositions and uses relating thereto
GB201616660D0 (en) Methods, compositions and uses relating thereto
GB201616666D0 (en) Methods, compositions and uses relating thereto
GB201518375D0 (en) Agents,uses and methods
GB201512211D0 (en) Agents, uses and methods
GB201512216D0 (en) Agents uses and methods
GB201616648D0 (en) Methods, compositions and uses relating thereto

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)